Agreement on nano-antibody drugs signed in Zhangjiang

Updated:2019-03-12 (zjsfq.gov.cn)

1552444309802006824.jpg

Shanghai Luoqi Biomedical Technology Co Ltd and Zhejiang Teruisi Biopharmaceutical Inc signs a global strategic cooperation agreement to develop tumor immunotherapy nano-antibody drugs. [Photo/WeChat account: shzjsfq]

Shanghai Luoqi Biomedical Technology Co Ltd and Zhejiang Teruisi Biopharmaceutical Inc recently signed a global strategic cooperation agreement.

The two sides will cooperate in various aspects in the field of tumor immunotherapy nano-antibody drugs.

Located in Shanghai's Zhangjiang National Innovation Demonstration Zone, Luoqi is one of China's leading enterprises in nano-antibody drugs R&D. It is committed to promoting their innovative development in China.

To date, the company has built a world-leading technology platform, with its production pipeline covering the four major sectors of tumor immunotherapy, autoimmune disease, ophthalmic disease and CAR-T treatment.

Teruisi is an innovative biopharmaceutical enterprise in Zhejiang province integrating R&D, pilot scaling and commercial production. The company focuses on the development of anti-tumor monoclonal antibody drugs.

According to Wan Yakun, chairman of Luoqi, as the two sides are both leaders in their respective fields, their cooperation will create a world-influential brand of nano-antibody drugs in China and promote allied industries.

8.03K